Latest News

STAT Plus: Myovant’s uterine fibroid drug meets goals in trial, setting up competition with AbbVie

A uterine fibroid treatment from Myovant Sciences met its goals in a second late-stage trial, setting the stage for Food and Drug Administration approval and competition with a pharmaceutical giant.

The drug, relugolix, significantly reduced menstrual blood loss, the most common symptom of uterine fibroids, and beat placebo on six other metrics including pain and quality of life, according to data released Tuesday. About 71% of women who took the daily pill responded to the therapy, experiencing at least a 50% reduction in blood loss over 24 weeks and falling below the FDA’s definition of heavy menstrual bleeding. The drug’s safety profile was similar to that of placebo, including on the key metric of bone density.

Continue to STAT Plus to read the full story…

Source link

Related posts

STAT Plus: Pharmalittle: Pharma keeps slashing jobs in the U.S.; overseas plants have more data integrity violations


Guidance updated for sedation in pediatric dental patients


Research warns of the far-reaching consequences of measles epidemic and failure to vaccinate


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World